Sign In
Buy TPST
$0.95
-0.0136 (-1.41%)
At Close: Jul 20, 2026
BRISBANE, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeut
Tempest Reports Year End 2023 Financial Results and Provides Business Update
04:25pm, Tuesday, 19'th Mar 2024
BRISBANE, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeut
Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)
03:56pm, Thursday, 14'th Mar 2024
NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Tempest Therapeutics, Inc. (Nasdaq: TPST) concerning the Company and its directors' and officers' poss
Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting
04:30pm, Tuesday, 05'th Mar 2024
BRISBANE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeut
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 02'nd Feb 2024
BRISBANE, Calif., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 05'th Jan 2024
BRISBANE, Calif., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:15pm, Friday, 01'st Dec 2023
BRISBANE, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and
Penny Stocks To Buy? 5 To Watch Right Now
11:16am, Wednesday, 22'nd Nov 2023
Penny stocks refer to shares of small or micro-cap companies that trade for less than $5 per share. What cheap stocks lack in size and stability, they can potentially make up for in rapid price change
Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference
08:00am, Monday, 20'th Nov 2023
BRISBANE, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and
Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update
05:17pm, Wednesday, 08'th Nov 2023
BRISBANE, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and
The Secrets Behind a 4000% Biotech Stock Surge
08:06am, Tuesday, 17'th Oct 2023
Remarkably, the stock did not have fundamentally changing news. It did not rocket higher on breaking news that would typically be associated with the whopping gains it experienced.
Ericsson shares drop on profit warning as NetScout stock slides on outlook cut
05:12am, Tuesday, 17'th Oct 2023
Tempest Therapeutics TPST, +85.16%, whose stock has gained 2710% over the last five days, saw its stock rise by 8% in premarket trade.
Tempest Therapeutics shares end wild week with 8% drop
04:13pm, Friday, 13'th Oct 2023
Shares of Tempest Therapeutics Inc. TPST, -8.54% fell more than 8% Friday to conclude a dramatic week in which the stock clocked a one-day gain of nearly 4,000%.
Tempest Therapeutics shares head back to earth after 4,000% gain
12:49pm, Thursday, 12'th Oct 2023
Shares of microcap oncology company Tempest Therapeutics Inc. TPST, -55.06% dropped more than 50% Thursday as investors took a breath after the stock's roughly 40-fold gain on Wednesday.
Tempest (TPST) Up as First-Line Liver Cancer Study Meets Goals
12:01pm, Thursday, 12'th Oct 2023
Tempest (TPST) skyrockets 2879% on positive new and updated findings from its early-mid-stage study evaluating TPST-1120 in combination with standard-of-care therapies to treat liver cancer.
